International Journal of Life science and Pharma Reviews (IJLPR)  
   
  Aim and Scope - To publish peer reviewed review articles in rapidly developing field of Pharma and life sciences  
 
Article
Life Science
Volume 12 Issue 3, May 2022    Pages:150-158
Molecular Determination of Virulence Factor Genes of Acinetobacter baumannii Isolates from Clinical Specimens

Fiji E, Anandharaj B, and Jijo G Varghese
[View PDF]
DOI: http://dx.doi.org/10.22376/ijpbs/lpr.2022.12.3.L150-158
Abstract:
Acinetobacter baumannii is a gram negative coccobacilli present abundantly in nature, in soil and water. Acinetobacter baumannii is considered as a major cause of nosocomial infections affecting mainly ICU patients and other hospitalised patients. Both intrinsic and acquired antibiotic resistance of A. baumannii account for a significant cause of outbreaks. Significant levels of morbidity and mortality have been reported with outbreaks and common infections include ventilator associated pneumonia and bacteraemia. A.baumannii is also a common cause of bloodstream infections in the intensive care setting. Multiple virulence factors are required for the pathogenesis of infections by Gram negative bacteria including A. baumannii. Possession of specialized virulence genes enables pathogens to infect hosts efficiently. Virulence factors of A. baumannii were less identified compared to other Gram negative bacteria. Hence this study was done to identify the major virulence factor genes from the clinical isolates of multidrug resistant A. baumannii from a tertiary care hospital. A preliminary study was done to determine the prevalence of Acinetobacter infections in the region and then the isolates were subjected to determine the antibiotic sensitivity and to various molecular typing. Various clinical specimens like blood, urine, abscess, vaginal swab were analyzed and 15% of the isolates was confirmed and identified as to be resistant to carbapenems. A molecular typing was done to identify the genes conferring virulence factors. Presence of different genes like Bap, Omp A, EpsA, ptk, AdeG were screened from the isolates.
Keywords: Acinetobacter baumannii, Virulence factor, Multi drug resistance, Molecular typing, Efflux pump, Biofilm, Capsular Polysaccharide
Full HTML:

1.Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: from bench to bedside. World J Clin Cases. 2014;2(12):787-814. doi: 10.12998/wjcc.v2.i12.787, PMID 25516853.

2.       Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81. doi: 10.1086/533452, PMID 18419525.

3.       WHO. List of bacteria for which new antibiotics are urgently needed. WHO; 2017.

4.       Al Atrouni A, Joly-Guillou ML, Hamze M, Kempf M. Reservoirs of non-baumannii Acinetobacter species. Front Microbiol. 2016;7:49. doi: 10.3389/fmicb.2016.00049, PMID 26870013.

5.       Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409-47. doi: 10.1128/CMR.00058-16, PMID 27974412.

6.       Garnacho M, Jose, Timsit JF. Managing Acinetobacter baumannii infections. Curr.Opi. Infect Dis. 2019;32(1):69-76.

7.       Matthieu E, Marie K, Olivier B, Helen P, Marie JGL. Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community acquired infections. Int J Infect Dis. 2013;17:e802-5.

8.       Tak-chiu WU. Carbapenem-resistant or multidrug resistant Acinetobacter baumannii – a clinician’s perspective. The Hong Kong. Med. Diar. 2011;16(4):6-9.

9.       Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148-65. doi: 10.1128/CMR.9.2.148, PMID 8964033.

10.      Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309-17. doi: 10.1086/421946, PMID 15306996.

11.      Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Med (Baltim). 1995;74(6):340-9. doi: 10.1097/00005792-199511000-00004, PMID 7500897.

12.      Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García-Garmendía JL et al. Bacteremia due to Acinetobacter baumannii:  epidemiology, clinical findings, and prognostic features. Clin Infect Dis.1996;22(6):1026-32. doi: 10.1093/clinids/22.6.1026, PMID 8783704.

13.      Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect. 2009;73(2):143-50. doi: 10.1016/j.jhin.2009.06.007, PMID 19716203.

14.      Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY et al. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis. 2010;10:228. doi: 10.1186/1471-2334-10-228, PMID 20670453.

15.      McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev. 2013;37(2):130-55. doi: 10.1111/j.1574-6976.2012.00344.x, PMID 22568581.

16.     Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology (Reading). 2003;149(12):3473-84. doi: 10.1099/mic.0.26541-0, PMID 14663080.

17.      McConoughey SJ, Howlin R, Granger JF, Manring MM, Calhoun JH, Shirtliff M, et al. Biofilms in periprosthetic orthopedic infections. Future Microbiol. 2014;9(8):987-1007. doi: 10.2217/fmb.14.64, PMID 25302955.

18.      Mietto C, Pinciroli R, Patel N, Berra L. Ventilator associated pneumonia: evolving definitions and preventive strategies. Respir Care. 2013;58(6):990-1007. doi: 10.4187/respcare.02380, PMID 23709196.

19.      Choi CH, Lee EY, Lee YC, Park TI, Kim HJ, Hyun SH et al. Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell Microbiol. 2005;7(8):1127-38. doi: 10.1111/j.1462-5822.2005.00538.x, PMID 16008580.

20.      Choi CH, Lee JS, Lee YC, Park TI, Lee JC. Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. BMC Microbiol. 2008;8:216. doi: 10.1186/1471-2180-8-216, PMID 19068136.

21.     Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH et al. Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins. FEMS Microbiol Lett. 2009;301(2):224-31. doi: 10.1111/j.1574-6968.2009.01820.x, PMID 19878322.

22.     Gaddy JA, Tomaras AP, Actis LA. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect Immun. 2009;77(8):3150-60. doi: 10.1128/IAI.00096-09, PMID 19470746.

23.      Loehfelm TW, Luke NR, Campagnari AA. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J Bacteriol. 2008;190(3):1036-44. doi: 10.1128/JB.01416-07, PMID 18024522.

24.      Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun. 2010 Sep;78(9):3993-4000. doi: 10.1128/IAI.00366-10. PMID 20643860, PMCID PMC2937447.

25.      Schneiders T, Findlay J, Amyes SG. Efflux Pumps in Acinetobacter baumannii. Acinetobacter Biology and pathogenesis. 2008:105-27.

26.      JaponiNejad AR, Sofian M, Ghaznavi-Rad E. Molecular detection of adeABC efflux pump genes in clinical isolates of Acinetobacter baumannii and their contribution in imipenem resistance. Iran S Med J. 2014;17(5):815-23.

27.      Nitzan Y, Pechatnikov I, Bar-El D, Wexler H. Isolation and characterization of heat-modifiable proteins from the outer membrane of Porphyromonas asaccharolytica and Acinetobacter baumannii. Anaerobe. 1999;5(1):43-50. doi: 10.1006/anae.1998.0181, PMID 16887661.

28.      Miller J, Miller S. A guide to specimen management in. Clin Microbiol. 2017. doi: 10.1128/9781555819620.

29.      Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne,PA: CLSI; 2020.

30.      Mobasseri P, Azimi L, Salehi M, Hosseini F, Fallah F. Distribution and expression of efflux pump gene and antibiotic resistance in Acinetobacter baumannii. Arch Clin Infect Dis. 2018;13(5):art no. e67143. doi: 10.5812/archcid.67143.

31.      Ali HM, Salem MZM, El-Shikh MS, Megeed AA, Alogaibi YA, Talea IA. Investigation of the virulence factors and molecularcharacterization of the clonal relations of multidrug-resistant Acinetobacter baumannii isolates. J AOAC Int. 2017;100(1):152-8. doi: 10.5740/jaoacint.16-0139, PMID 27765082.

32.      Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun. 2010 Sep;78(9):3993-4000. doi: 10.1128/IAI.00366-10. PMID 20643860, PMCID PMC2937447.

33.      Ibrahim ME. Prevalence of Acinetobacter baumannii in Saudi Arabia: risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance. Ann Clin Microbiol Antimicrob. 2019;18(1):1. doi: 10.1186/s12941-018-0301-x, PMID 30606201.

34.      Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage rooklyn, New York: City wilde prevalence. Clin Infect Dis. 2000;31(1):101-6. doi: 10.1086/313902, PMID 10913404.

35.      Rit K, Saha R. Multidrug-resistant Acinetobacter infection and their susceptibility patterns in a tertiary care hospital. Niger Med J. 2012;53(3):126-8. doi: 10.4103/0300-1652.104379, PMID 23293410.

36.      Owlia P, Azimi L, Gholami A, Asghari B, Lari AR. ESBL- and MBL-mediated resistance in Acinetobacter baumannii: a global threat to burn patients. Infez Med. 2012;20(3):182-7. PMID 22992558.

37.     Cortivo GD, Gutberlet A, Ferreira JA, Ferreira LE, Deglmann RC, Westphal GA, et al. Antimicrobial resistance profiles and oxacillinase genes in carbapenem-resistant Acinetobacter baumannii isolated from hospitalized patients in Santa Catarina, Brazil. Rev Soc Bras Med Trop. 2015;48(6):699-705. doi: 10.1590/0037-8682-0233-2015, PMID 26676494.

38.      Ghajavand H, Esfahani BN, Havaei SA, Moghim S, Fazeli H. Molecular identification of Acinetobacter baumannii isolated from intensive care units and their antimicrobial resistance patterns. Adv Biomed Res. 2015;4:110. doi: 10.4103/2277-9175.157826, PMID 26261812.

39.      Ghasemi E, Ghalavand Z, Goudarzi H, Yeganeh F, Hashemi A, Dabiri H et al. Phenotypic and genotypic investigation of biofilm formation in clinical and environmental isolates of Acinetobacter baumannii. Arch Clin Infect Dis. 2018;13(4):e12914. doi: 10.5812/archcid.12914.

40.      Thummeepak R, Kongthai P, Leungtongkam U, Sitthisak S. Distribution of virulence genes involved in biofilm formation in multi-drug resistant Acinetobacter baumannii clinical isolates. Int Microbiol. 2016;19(2):121-9. doi: 10.2436/20.1501.01.270, PMID 27845499.

41.     Youn Sung J. Molecular characterization and antimicrobial susceptibility of biofilm-forming Acinetobacter baumannii clinical isolates from Daejeon, Korea. Vol. 50; 2018.

42.      Qi L, Li H, Zhang C, Liang B, Li J, Wang L et al. Relationship between Antibiotic Resistance, Biofilm Formation, and Biofilm-Specific Resistance in Acinetobacter baumannii. Front Microbiol. 2016;7:483. doi: 10.3389/fmicb.2016.00483, PMID 27148178.

43.      Schneiders T, Findlay J, Amyes SG. Efflux pumps in Acinetobacter baumannii. Acinetobacter Biology and pathogenesis. 2008:105-27.

44.      Rosenfeld N, Bouchier C, Courvalin P, Périchon B. Expression of the resistance-nodulation-cell division pump adeIJK in Acinetobacter baumannii is regulated by adeN, a TetR-type regulator. Antimicrob Agents Chemother. 2012;56(5):2504-10. doi: 10.1128/AAC.06422-11, PMID 22371895.

45.      Coyne S, Rosenfeld N, Lambert T, Courvalin P, Périchon B. Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(10):4389-93. doi: 10.1128/AAC.00155-10, PMID 20696879.

46.      Sun JR, Perng CL, Lin JC, Yang YS, Chan MC, Chang TY, et al. AdeRS combination codes differentiate the response to efflux pump inhibitors in tigecycline-resistant isolates of extensively drug-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2014;33(12):2141-7. doi: 10.1007/s10096-014-2179-7, PMID 24939621.

 

 

 
© 2010-2015 IJLPR rights reserved. Specialized onine journals by ubijournal. Website by Ubitech Solutions